Category: Featured

Race Oncology Limited is pleased to announce the successful completion of a $1.45 million placement, led by prominent biotechnology investor Dr Daniel Tillett. The placement comprised 21.9 million new ordinary shares at an issue price of $0.066 (6.6 cents) per…

Race Oncology has announced it has secured a new patent on its cancer drug, Bisantrene, from the United States Patent and Trademarks Office (USPTO). This is Race’s third patent granted on Bisantrene in the United States. “The new US patent…

Race Oncology is pleased to announce it has successfully completed treatment on its first patient at the Sheba Medical Center in Israel as part of its Bisantrene trial at the facility. The patient diagnosed with relapsed/refractory Acute Myeloid Leukaemia (AML)…

Race Oncology has announced that it has signed an agreement to conduct a trial of Race’s cancer drug, Bisantrene, at the Sheba Medical Center in Israel. The trial has been approved by the Israeli Ministry of Health and the hospital’s…

Race Oncology is pleased to announce that Dr Roland Walter has agreed to be the Principal Investigator for the US registration trial for Bisantrene. Roland B. Walter, MD PhD MS, is a leading international haematologist and AML expert, based at…

Race Oncology is pleased to announce that it has executed a consulting agreement with Professor Borje Andersson from the M.D. Anderson Cancer Research Center in Houston, Texas. Under the initial 12-month agreement, Professor Andersson will be engaged to: Advise Race Oncology…

Race Oncology is very pleased to announce that it has executed a Named Patient Program (NPP) distribution and sales agreement in Israel with TrueMed Ltd. According to Race, TrueMed is a pharmaceutical distributor with experience in driving NPPs in Israel.…

Race Oncology is pleased to announce it has executed a services agreement with BioSynergy Partners LLC (BioSynergy) to pursue licensing and other deals for Bisantrene (the ‘Agreement’). BioSynergy is a transaction consulting business owned by Dr John Cullity, a non-executive…

Race Oncology is pleased to announce that it has executed an agreement with Mr Tom Lee to assist Race with partnering and funding opportunities in the US, with a focus on Houston, Texas. Mr Lee is well-connected to the MD Anderson…

Race Oncology is pleased to announce that it has received a letter from the FDA advising that Bisantrene has been granted Rare Paediatric Disease (RPD) designation for the treatment of childhood Acute Myeloid Leukaemia (AML). The RPD designation means Bisantrene has…